134 related articles for article (PubMed ID: 37827881)
1. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
Rojek AE; Kline JP; Feinberg N; Appelbaum DE; Pu Y; Derman BA; Jakubowiak A; Kosuri S; Liu H; Nawas MT; Smith SM; Bishop MR; Riedell PA
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):83-93. PubMed ID: 37827881
[TBL] [Abstract][Full Text] [Related]
2. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Hubbeling H; Silverman EA; Michaud L; Tomas AA; Shouval R; Flynn J; Devlin S; Wijetunga NA; Tringale KR; Batlevi C; Dahi P; Giralt S; Lin R; Park J; Scordo M; Sauter C; Shah G; Hajj C; Salles G; Schoder H; Palomba ML; Perales MA; Yahalom J; Imber BS
Transplant Cell Ther; 2023 Apr; 29(4):259.e1-259.e10. PubMed ID: 36587744
[TBL] [Abstract][Full Text] [Related]
3. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
[TBL] [Abstract][Full Text] [Related]
4. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.
Ababneh HS; Ng AK; Abramson JS; Soumerai JD; Takvorian RW; Frigault MJ; Patel CG
Hematol Oncol; 2024 Jan; 42(1):e3231. PubMed ID: 37795759
[TBL] [Abstract][Full Text] [Related]
5. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.
Wang J; Hu Y; Yang S; Wei G; Zhao X; Wu W; Zhang Y; Zhang Y; Chen D; Wu Z; Xiao L; Chang AH; Huang H; Zhao K
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1092-1098. PubMed ID: 30769193
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Winkelmann M; Blumenberg V; Rejeski K; Bücklein VL; Ruzicka M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1406-1413. PubMed ID: 36513818
[TBL] [Abstract][Full Text] [Related]
7. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy.
Iacoboni G; Simó M; Villacampa G; Catalá E; Carpio C; Díaz-Lagares C; Vidal-Jordana Á; Bobillo S; Marín-Niebla A; Pérez A; Jiménez M; Abrisqueta P; Bosch F; Barba P
Ann Hematol; 2021 Sep; 100(9):2303-2310. PubMed ID: 34236497
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
12. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by
Lutfi F; Goloubeva O; Kowatli A; Gryaznov A; Kim DW; Dureja R; Margiotta P; Matsumoto LR; Bukhari A; Ahmed N; Mushtaq MU; Law JY; Lee ST; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; McGuirk JP; Rapoport AP; Chen W; Dahiya S
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):757-763. PubMed ID: 37453865
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
Georgi TW; Kurch L; Franke GN; Jentzsch M; Schwind S; Perez-Fernandez C; Petermann N; Merz M; Metzeler K; Borte G; Hoffmann S; Herling M; Denecke T; Kluge R; Sabri O; Platzbecker U; Vučinić V
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6131-6138. PubMed ID: 36662305
[TBL] [Abstract][Full Text] [Related]
15. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P
Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
17. The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy.
Garcia-Recio M; Wudhikarn K; Pennisi M; Alonso-Trillo R; Flynn J; Shouval R; Afuye AO; Silverberg ML; Batlevi CW; Dahi P; Devlin S; Giralt SA; Halton E; Ruiz J; Maloy M; Mead E; Palomba ML; Santomasso B; Sauter CS; Scordo M; Shah GL; Perales MA
Transplant Cell Ther; 2021 Mar; 27(3):233-240. PubMed ID: 33781518
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement.
Kupik O; Akin S; Tuncel M; Eren G; Türker A; Kars A; Erbaş B
Nucl Med Commun; 2020 Jun; 41(6):540-549. PubMed ID: 32209829
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
20. CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers.
Mussetti A; Fabbri N; Sureda A
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):357-363. PubMed ID: 38066912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
